Concepts (221)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocardial Infarction | 8 | 2022 | 864 | 2.150 |
Why?
|
| Vietnam | 15 | 2024 | 160 | 1.130 |
Why?
|
| Hospitalization | 6 | 2018 | 1283 | 1.030 |
Why?
|
| Hypertension | 6 | 2023 | 601 | 0.930 |
Why?
|
| Patients | 2 | 2021 | 102 | 0.850 |
Why?
|
| Clinical Laboratory Services | 1 | 2021 | 5 | 0.760 |
Why?
|
| Medical Laboratory Personnel | 1 | 2021 | 8 | 0.760 |
Why?
|
| Hospital Mortality | 5 | 2022 | 846 | 0.740 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2022 | 76 | 0.730 |
Why?
|
| Shock, Cardiogenic | 2 | 2022 | 85 | 0.730 |
Why?
|
| Patient Education as Topic | 3 | 2023 | 446 | 0.660 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 442 | 0.600 |
Why?
|
| Sample Size | 1 | 2017 | 59 | 0.570 |
Why?
|
| Hospital Administration | 2 | 2014 | 41 | 0.570 |
Why?
|
| Aged | 20 | 2024 | 13339 | 0.560 |
Why?
|
| Life Style | 1 | 2018 | 328 | 0.550 |
Why?
|
| Forecasting | 1 | 2017 | 221 | 0.530 |
Why?
|
| Healthcare Disparities | 2 | 2010 | 330 | 0.530 |
Why?
|
| Sex Factors | 4 | 2014 | 960 | 0.520 |
Why?
|
| Health Behavior | 1 | 2018 | 473 | 0.490 |
Why?
|
| Patient Selection | 1 | 2017 | 446 | 0.480 |
Why?
|
| Cardiovascular Diseases | 3 | 2020 | 827 | 0.480 |
Why?
|
| Male | 26 | 2024 | 27567 | 0.460 |
Why?
|
| Developing Countries | 4 | 2023 | 84 | 0.450 |
Why?
|
| Female | 27 | 2024 | 30913 | 0.430 |
Why?
|
| Age Factors | 4 | 2018 | 1518 | 0.420 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2019 | 741 | 0.420 |
Why?
|
| Sex Characteristics | 1 | 2014 | 198 | 0.410 |
Why?
|
| Risk Assessment | 2 | 2017 | 1914 | 0.400 |
Why?
|
| Aedes | 4 | 2016 | 12 | 0.400 |
Why?
|
| Humans | 40 | 2024 | 59512 | 0.400 |
Why?
|
| Acute Coronary Syndrome | 2 | 2018 | 258 | 0.400 |
Why?
|
| Dengue | 4 | 2016 | 93 | 0.390 |
Why?
|
| Dengue Virus | 3 | 2015 | 95 | 0.350 |
Why?
|
| Myocardial Revascularization | 1 | 2010 | 71 | 0.340 |
Why?
|
| Outpatients | 2 | 2022 | 131 | 0.340 |
Why?
|
| Nurses | 2 | 2021 | 103 | 0.330 |
Why?
|
| Middle Aged | 14 | 2022 | 16275 | 0.330 |
Why?
|
| Cardiovascular Agents | 1 | 2010 | 100 | 0.330 |
Why?
|
| Noncommunicable Diseases | 2 | 2019 | 16 | 0.320 |
Why?
|
| Transportation of Patients | 1 | 2009 | 42 | 0.320 |
Why?
|
| Patient Satisfaction | 3 | 2021 | 410 | 0.320 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 5089 | 0.310 |
Why?
|
| Heart Block | 1 | 2008 | 23 | 0.300 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 452 | 0.300 |
Why?
|
| Inpatients | 1 | 2010 | 296 | 0.290 |
Why?
|
| Prognosis | 4 | 2018 | 1572 | 0.270 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 2329 | 0.250 |
Why?
|
| Incidence | 5 | 2018 | 1237 | 0.250 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2009 | 446 | 0.250 |
Why?
|
| Adult | 15 | 2023 | 15784 | 0.250 |
Why?
|
| Pharmacists | 3 | 2020 | 123 | 0.220 |
Why?
|
| Risk Factors | 6 | 2018 | 5015 | 0.210 |
Why?
|
| Adenoma | 1 | 2023 | 63 | 0.210 |
Why?
|
| Esophagitis | 1 | 2022 | 9 | 0.210 |
Why?
|
| Peptic Ulcer | 1 | 2022 | 21 | 0.210 |
Why?
|
| Coronary Artery Bypass | 2 | 2018 | 274 | 0.210 |
Why?
|
| Pain Measurement | 2 | 2021 | 330 | 0.200 |
Why?
|
| Gastroesophageal Reflux | 1 | 2022 | 77 | 0.200 |
Why?
|
| Propofol | 1 | 2022 | 27 | 0.200 |
Why?
|
| Ketamine | 1 | 2022 | 33 | 0.190 |
Why?
|
| Public Health | 2 | 2021 | 180 | 0.190 |
Why?
|
| Treatment Outcome | 5 | 2018 | 5183 | 0.190 |
Why?
|
| Mobile Applications | 1 | 2023 | 130 | 0.190 |
Why?
|
| Drug Hypersensitivity | 1 | 2021 | 28 | 0.180 |
Why?
|
| Blood Culture | 1 | 2020 | 12 | 0.180 |
Why?
|
| Dementia | 1 | 2024 | 247 | 0.180 |
Why?
|
| Time Factors | 4 | 2018 | 3579 | 0.180 |
Why?
|
| Atrial Fibrillation | 2 | 2018 | 798 | 0.170 |
Why?
|
| Pharmacy Technicians | 1 | 2019 | 3 | 0.170 |
Why?
|
| Frailty | 1 | 2022 | 125 | 0.170 |
Why?
|
| Surveys and Questionnaires | 4 | 2021 | 2592 | 0.170 |
Why?
|
| Videotape Recording | 1 | 2019 | 46 | 0.160 |
Why?
|
| Bacteremia | 1 | 2020 | 94 | 0.160 |
Why?
|
| Computers, Handheld | 1 | 2019 | 32 | 0.160 |
Why?
|
| Perception | 1 | 2020 | 179 | 0.160 |
Why?
|
| Stakeholder Participation | 1 | 2019 | 22 | 0.160 |
Why?
|
| Pandemics | 2 | 2023 | 608 | 0.160 |
Why?
|
| Hospitals | 1 | 2022 | 376 | 0.160 |
Why?
|
| Infection Control | 1 | 2020 | 96 | 0.160 |
Why?
|
| Pharmaceutical Services | 1 | 2019 | 31 | 0.160 |
Why?
|
| Massachusetts | 3 | 2017 | 2089 | 0.160 |
Why?
|
| Prospective Studies | 4 | 2023 | 3101 | 0.160 |
Why?
|
| Patient Compliance | 1 | 2021 | 372 | 0.160 |
Why?
|
| Prevalence | 3 | 2022 | 1281 | 0.160 |
Why?
|
| Warfarin | 1 | 2019 | 109 | 0.160 |
Why?
|
| Insect Vectors | 2 | 2015 | 14 | 0.150 |
Why?
|
| Short Bowel Syndrome | 1 | 2018 | 5 | 0.150 |
Why?
|
| Growth | 1 | 2018 | 22 | 0.150 |
Why?
|
| Talaromyces | 1 | 2017 | 1 | 0.150 |
Why?
|
| Itraconazole | 1 | 2017 | 13 | 0.150 |
Why?
|
| Minority Groups | 1 | 2019 | 140 | 0.150 |
Why?
|
| Dermatomycoses | 1 | 2017 | 13 | 0.150 |
Why?
|
| Growth Disorders | 1 | 2018 | 30 | 0.150 |
Why?
|
| Multiple Chronic Conditions | 1 | 2018 | 34 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 669 | 0.140 |
Why?
|
| Rural Population | 1 | 2019 | 191 | 0.140 |
Why?
|
| Poverty | 1 | 2019 | 286 | 0.140 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 187 | 0.140 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 199 | 0.140 |
Why?
|
| Child Development | 1 | 2018 | 79 | 0.140 |
Why?
|
| Single-Blind Method | 1 | 2017 | 133 | 0.140 |
Why?
|
| Antifungal Agents | 1 | 2017 | 117 | 0.140 |
Why?
|
| Medication Adherence | 1 | 2019 | 255 | 0.140 |
Why?
|
| Quality of Life | 1 | 2024 | 1117 | 0.140 |
Why?
|
| Mosquito Control | 1 | 2016 | 6 | 0.130 |
Why?
|
| Insect Repellents | 1 | 2016 | 2 | 0.130 |
Why?
|
| Biomedical Research | 1 | 2019 | 250 | 0.130 |
Why?
|
| Cause of Death | 1 | 2017 | 200 | 0.130 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 421 | 0.130 |
Why?
|
| Culture | 2 | 2016 | 76 | 0.130 |
Why?
|
| Pilot Projects | 2 | 2019 | 919 | 0.130 |
Why?
|
| Wolbachia | 1 | 2015 | 3 | 0.120 |
Why?
|
| Opioid-Related Disorders | 1 | 2022 | 465 | 0.120 |
Why?
|
| Clinical Protocols | 1 | 2016 | 134 | 0.120 |
Why?
|
| Income | 3 | 2021 | 160 | 0.120 |
Why?
|
| Respiratory Tract Infections | 1 | 2015 | 80 | 0.120 |
Why?
|
| Health Education | 1 | 2016 | 184 | 0.110 |
Why?
|
| Viruses | 1 | 2015 | 79 | 0.110 |
Why?
|
| Virus Diseases | 1 | 2015 | 110 | 0.110 |
Why?
|
| Pain | 3 | 2022 | 406 | 0.110 |
Why?
|
| Caregivers | 1 | 2016 | 216 | 0.110 |
Why?
|
| Retrospective Studies | 5 | 2022 | 6008 | 0.100 |
Why?
|
| Odds Ratio | 2 | 2012 | 773 | 0.100 |
Why?
|
| Comorbidity | 1 | 2014 | 1091 | 0.090 |
Why?
|
| Physicians | 1 | 2016 | 436 | 0.090 |
Why?
|
| South America | 1 | 2010 | 22 | 0.090 |
Why?
|
| New Zealand | 1 | 2010 | 34 | 0.090 |
Why?
|
| Smoking Prevention | 1 | 2012 | 162 | 0.090 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2010 | 26 | 0.090 |
Why?
|
| North America | 1 | 2010 | 114 | 0.090 |
Why?
|
| Australia | 1 | 2010 | 94 | 0.090 |
Why?
|
| Europe | 1 | 2010 | 183 | 0.090 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 142 | 0.080 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2010 | 149 | 0.080 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2010 | 167 | 0.080 |
Why?
|
| Aspirin | 1 | 2010 | 186 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 436 | 0.080 |
Why?
|
| Ambulatory Care Facilities | 2 | 2019 | 102 | 0.080 |
Why?
|
| Young Adult | 5 | 2019 | 4329 | 0.080 |
Why?
|
| Acute Disease | 1 | 2010 | 659 | 0.080 |
Why?
|
| Logistic Models | 2 | 2012 | 1252 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 212 | 0.080 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2010 | 252 | 0.080 |
Why?
|
| Adaptation, Psychological | 1 | 2009 | 262 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 2 | 2020 | 299 | 0.070 |
Why?
|
| Registries | 1 | 2010 | 803 | 0.070 |
Why?
|
| Smoking Cessation | 1 | 2012 | 531 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 2468 | 0.070 |
Why?
|
| Adolescent | 4 | 2020 | 5930 | 0.070 |
Why?
|
| Quality of Health Care | 1 | 2010 | 519 | 0.070 |
Why?
|
| Data Collection | 2 | 2019 | 384 | 0.060 |
Why?
|
| Quarantine | 1 | 2023 | 10 | 0.050 |
Why?
|
| Ghana | 1 | 2023 | 10 | 0.050 |
Why?
|
| Cathartics | 1 | 2023 | 11 | 0.050 |
Why?
|
| Kenya | 1 | 2023 | 81 | 0.050 |
Why?
|
| Esophageal Sphincter, Lower | 1 | 2022 | 20 | 0.050 |
Why?
|
| Manometry | 1 | 2022 | 22 | 0.050 |
Why?
|
| Colonoscopy | 1 | 2023 | 103 | 0.050 |
Why?
|
| Infant, Newborn | 2 | 2018 | 1311 | 0.050 |
Why?
|
| Activities of Daily Living | 1 | 2024 | 298 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2022 | 170 | 0.050 |
Why?
|
| Infant | 2 | 2018 | 1527 | 0.050 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2022 | 117 | 0.050 |
Why?
|
| Absorptiometry, Photon | 1 | 2022 | 89 | 0.050 |
Why?
|
| Fentanyl | 1 | 2022 | 70 | 0.050 |
Why?
|
| Analgesics | 1 | 2022 | 100 | 0.050 |
Why?
|
| Developed Countries | 1 | 2021 | 15 | 0.050 |
Why?
|
| Penicillins | 1 | 2021 | 28 | 0.050 |
Why?
|
| Personal Satisfaction | 1 | 2021 | 77 | 0.050 |
Why?
|
| Frail Elderly | 1 | 2022 | 110 | 0.050 |
Why?
|
| Geriatric Assessment | 1 | 2022 | 161 | 0.050 |
Why?
|
| Pathology, Molecular | 1 | 2020 | 10 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2020 | 104 | 0.040 |
Why?
|
| Community Health Workers | 1 | 2020 | 37 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2022 | 294 | 0.040 |
Why?
|
| United States | 3 | 2018 | 7511 | 0.040 |
Why?
|
| Telephone | 1 | 2019 | 121 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 160 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2018 | 95 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2022 | 449 | 0.040 |
Why?
|
| Parenteral Nutrition | 1 | 2018 | 21 | 0.040 |
Why?
|
| Nursing Homes | 1 | 2024 | 665 | 0.040 |
Why?
|
| Enteral Nutrition | 1 | 2018 | 56 | 0.040 |
Why?
|
| Animals | 4 | 2016 | 19660 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 496 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2018 | 118 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 1551 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2019 | 484 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2017 | 344 | 0.030 |
Why?
|
| Family Characteristics | 1 | 2016 | 44 | 0.030 |
Why?
|
| Survival Rate | 1 | 2018 | 791 | 0.030 |
Why?
|
| Exercise | 1 | 2023 | 916 | 0.030 |
Why?
|
| Disease Vectors | 1 | 2015 | 7 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 13 | 0.030 |
Why?
|
| Nasopharynx | 1 | 2015 | 21 | 0.030 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2015 | 17 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2018 | 352 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2019 | 487 | 0.030 |
Why?
|
| Viremia | 1 | 2015 | 44 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2016 | 196 | 0.030 |
Why?
|
| Skin | 1 | 2017 | 353 | 0.030 |
Why?
|
| Saliva | 1 | 2015 | 96 | 0.030 |
Why?
|
| Host-Parasite Interactions | 1 | 2015 | 54 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2015 | 158 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2019 | 425 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 724 | 0.030 |
Why?
|
| Length of Stay | 1 | 2018 | 771 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2018 | 479 | 0.030 |
Why?
|
| Longevity | 1 | 2015 | 111 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 526 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2015 | 258 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2016 | 388 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2018 | 1839 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2012 | 98 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 256 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2012 | 147 | 0.020 |
Why?
|
| Psychometrics | 1 | 2012 | 356 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 2442 | 0.020 |
Why?
|
| Pregnancy | 1 | 2015 | 2355 | 0.020 |
Why?
|
| Smoking | 1 | 2012 | 830 | 0.020 |
Why?
|